Navigation Links
Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model
Date:4/8/2008

Research To Be Presented at American Association of Immunologists Meeting

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research being presented at the American Association of Immunologists meeting in San Diego, California on April 8, 2008. Using Rigel's R788, researchers from the Department of Medicine at Columbia University Medical Center have shown that blocking Syk kinase in a well-established murine model of type 1 diabetes, delayed the onset of diabetes and prolonged survival. A reduction in the production of insulin-specific autoantibodies, an early event in type 1 diabetes pathogenesis, was also observed.

"Inhibition of the Syk kinase has the potential to reduce both autoantibody production and disarm its pathogenic consequences," said Raphael Clynes M.D., Ph.D., assistant professor in Medicine and Microbiology at Columbia University's College of Physician's and Surgeons. "In diabetes, autoantibodies against islet cells appear before the actual onset of disease providing the opportunity to intervene and disable these early events prior to immune destruction of the insulin-producing cells in the pancreas. The protection we see in these mouse models suggests that pharmacologic blockade of Syk with R788 may provide a good therapeutic strategy to treat and potentially prevent the onset or advancement of type 1 diabetes," he added.

Type 1 Diabetes and R788

According to the Juvenile Diabetes Research Foundation, type 1 diabetes, also called juvenile diabetes or insulin-dependent diabetes, occurs when the body's immune syst
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
2. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
3. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
6. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
7. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
8. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
9. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
10. Newly Approved HIV Drug Shows Great Promise
11. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Inc. ( www.synapsebiomedical.com ) announced today it has ... its NeuRx DPS® System for ALS patients.  The ... requirement was implanted over a month and a ... is the only medical device approved by the ... device that obtained approval at the end of ...
(Date:9/30/2014)... Netherlands , Sept. 30, 2014  eHealth, ... phone storage and access of this information, has ... Slot , however, that has not translated into ... http://photos.prnewswire.com/prnh/20140929/149122 Photo - http://photos.prnewswire.com/prnh/20140929/149123 ... the past few years developing MWD® Health Manager ...
(Date:9/30/2014)... 30, 2014 It is evident from the industry ... not performing upto expectations due to the lack of promotional ... the intake of omega-3 fatty acids. Among omega-3 ingredient sources ... oil, attributed to the large vegetarian population in ... fatty acid (PUFAs) ingredients is in growth stage of its ...
Breaking Medicine Technology:Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 2Synapse Biomedical Announces the Early Completion of Enrollment in the FDA Post Approval Study for ALS Patients 3MWD Challenges the Big eHealth Players With New Software for Your Smartphone 2Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2
... FRANCISCO, Oct. 29 Medivation, Inc. (Nasdaq: MDVN ... webcast with management to discuss third quarter 2010 financial results ... at 4:30 p.m. Eastern Time. A press release for the ... markets close on November 5, 2010. Interested ...
... N.Y., Oct. 29 Henry Schein, Inc. (Nasdaq: ... to office-based practitioners, today reported record financial results for the ... the third quarter of 2010 were $1.9 billion, an increase ... consists of 16.4% growth in local currencies and a decline ...
Cached Medicine Technology:Henry Schein Reports Record Third Quarter Results 2Henry Schein Reports Record Third Quarter Results 3Henry Schein Reports Record Third Quarter Results 4Henry Schein Reports Record Third Quarter Results 5Henry Schein Reports Record Third Quarter Results 6Henry Schein Reports Record Third Quarter Results 7Henry Schein Reports Record Third Quarter Results 8Henry Schein Reports Record Third Quarter Results 9Henry Schein Reports Record Third Quarter Results 10Henry Schein Reports Record Third Quarter Results 11
(Date:9/30/2014)... Visit Pam and Steve’s quiet home in the ... a loving couple facing the most monumental challenge of ... Steve was diagnosed with ALS – more commonly known ... the couple’s second wedding anniversary. Pam is now ... “Care, Support & ALS,” that’s part of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 A highlight ... Optics (AMO) at the American Academy of Ophthalmology meeting ... LASIK surgeon Jeffrey Martin, MD on the ... is the Managing Partner of North Shore Eye Care ... SUNY Stony Brook. , This year’s 118th Annual American ...
(Date:9/30/2014)... News) -- Herceptin is the best drug treatment for ... remain the standard of care for that type of ... trial. HER2-positive breast cancers tend to be more ... the Mayo Clinic. For the study, more than ... or Tykerb (lapatinib) in addition to standard chemotherapy. ...
(Date:9/30/2014)... September 30, 2014 The St. Louis ... SLUCare Physician Group, comprised of more than 500 physicians, ... number of initiatives. With the recent addition of ... strengthening its market footprint to better respond to the ... , SLPA is a physician-led clinically integrated network (CIN) ...
(Date:9/30/2014)... Francisco, California (PRWEB) September 30, 2014 ... expected to reach USD 8,020.1 million by 2020, ... Research, Inc. Growing demand for personalized medicine and ... diagnostic technologies are expected to be key factors ... Moreover, the growing global base of geriatric population ...
Breaking Medicine News(10 mins):Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:Global Laser Technology Leader Selects Jeffrey Martin, MD To Address Colleagues During International Symposium In Chicago 2014 2Health News:Global Laser Technology Leader Selects Jeffrey Martin, MD To Address Colleagues During International Symposium In Chicago 2014 3Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6
... has invited best-selling author and noted physician Abraham Verghese to ... and Human Values at 7:30 p.m., Monday, Oct. 24 at ... Indian-American immigrant to the United States, Dr. Verghese,s varied professional ... India studies program at UH," said Lois Zamora, chair of ...
... Phase III trial of RTS,S*, published online today in the ... malaria vaccine candidate to provide young African children with significant ... and tolerability profile. The results were announced today at the ... in Seattle, Washington. Half the world,s population is at ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay ... conventional Pap tests as a cervical cancer screening tool ... The U.S. Preventive Services Task Force ... researchers are now seeking to fine-tune these guidelines. The ...
... (IAN Project) launches a national survey to study the ... (ASD). Bullying, a pervasive problem among youth, has attracted ... lasting, and sometimes tragic, effects on children and teenagers ... be especially vulnerable targets due to their social deficits ...
... (HealthDay News) -- Experts at the American Academy of Pediatrics ... for sudden infant death syndrome (SIDS). Those are two ... SIDS guidelines. Since 1992, when the AAP recommended that ... SIDS has declined sharply in the United States, according to ...
... Cypress, CA, October 18, 2011 Technology has radically ... this more evident than in the field of gynecologic ... teaching minimally invasive treatment for women,s health problems, will ... tools among the hundreds of postgraduate courses and practice ...
Cached Medicine News:Health News:Dr. Abraham Verghese to give John P. McGovern Lecture on Oct. 24 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 3Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 3Health News:National survey will measure how bullying impacts children with autism 2Health News:Breast-Feeding, Vaccinations Lower SIDS Risk, Experts Say 2Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 2Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 3Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 4
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: